Earnings Releases·Nov 12, 2026, 7:02 AM ET

Kiora Pharmaceuticals — Third Quarter 2026 Earnings Summary

Reported $1.0 million in total revenue driven by the CKD collaboration, contrasting with $0 in the prior-year quarter, while net loss widened to $1.7 million ($0.28/share) from $27,000 net income previously.
Initiated planning for a multinational Phase 3 trial of KIO-401 in CRAO, submitted Type B pre-IND and orphan drug designation requests to the FDA, and confirmed KIO-301 ABACUS-2 data is on track for end-of-2027.
Discontinued R&D investment in KIO-104 to enhance financial flexibility, while cash and short-term investments decreased to $16.3 million from $17.1 million at year-end 2025.
Appointed Keith Lane as EVP of Clinical Development and Regulatory Affairs to lead the expanded team, with management committing to a streamlined operation aligned with development milestones.